The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Marchenkova L.A.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo

Dreval' A.V.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo

Kriukova I.V.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo

Vishniakova M.V.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo

Poliakova E.Iu.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo

Tishenina R.S.

Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo

Rubin M.P.

GKB #23 im. Medsantrud, Moskva

Efficacy and safety of Bivalos therapy in patients with postmenopausal osteoporosis without calcium and vitamin D supplement

Authors:

Marchenkova L.A., Dreval' A.V., Kriukova I.V., Vishniakova M.V., Poliakova E.Iu., Tishenina R.S., Rubin M.P.

More about the authors

Journal: Problems of Endocrinology. 2010;56(1): 35‑41

Read: 1137 times


To cite this article:

Marchenkova LA, Dreval' AV, Kriukova IV, Vishniakova MV, Poliakova EIu, Tishenina RS, Rubin MP. Efficacy and safety of Bivalos therapy in patients with postmenopausal osteoporosis without calcium and vitamin D supplement. Problems of Endocrinology. 2010;56(1):35‑41. (In Russ.)

Recommended articles:
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Vita­min D role in oral cavity diseases. Stomatology. 2025;(1):81-86
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73

References:

  1. Bell N.H., Bilezikian J.P. et al. Alendronate increases bone mass and reduces markers in postmenopausal African-American women J Clin Endocrinol Metabol 2002; 87: 6: 2792-2797.
  2. Black D.M., Delmas P.D., Estell R. et al. Once-early zoledronic acid for treatment of postmenopausal octeoporosis. N Engl J Med 2007; 356: 1809-1822.
  3. Neer R.M., Arnaud C.D., Zanchetta J.R. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. Engl J Med 2001; 35: 1434-1441.
  4. Caverzasio J. et al. Strontium ranelate increases osteoblast replication through activation of an original cellular mechanism. Calcified Tissue Int 2007; 80 (suppl 1): S74.
  5. Canalis E., Hott M. et al. The divalent strontium solt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996: 18: 517-523.
  6. Atkins G.J., Welldon K.J., Findlay D.M. et al. Strontium ranelate promotes an osteocyte-like phenotype from human primary osteoblasts ex vivo. Calcified Tissue Int 2007; 80 (suppl 1): 71-72.
  7. Rozhinskaya L.Ya., Belyaeva A.V., Belaya Zh.E. Ranelat strontsiya (Bivalos) - preparat dvoinogo deistviya na kostnuyu tkan'; novye podkhody k lecheniyu osteoporoza. Osteoporoz i osteopatii 2006; 1: 32-37.
  8. Osteoporoz: diagnostika, profilaktika i lechenie (klinicheskie rekomendatsii). Pod red. O.M. Lesnyak, L.I. Benevolenskoi 2-e izd. M: GEOTAR-Media 2009; 272.
  9. Marquis P., Roux C., de la Loge C. et al. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteopor Int 2008; 19: 4: 503-510.
  10. Meunier P.J., Roux C., Seeman E. et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New Eng J Med 2004; 350: 459-468.
  11. Reginster J..Y, Seeman E., De Vernejoul M.C. et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 5: 2816-2822.
  12. Rizzoli R., Boonen S., Brandi M.L. et al. The role of calcium and vitamin D in the management of osteoporosis. Bone 2008; 42: 246-249.
  13. Lips P., Cooper C., Agnusdei D. et al. Quality of life in patients with vertebral fractures: validation of the quality of life questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Osteopor Int 1999; 10: 150-160. doi: 10.1007 s001980050210.
  14. Lips P., Cooper C. Qualeffo-41 scoring algorithm (updated 31.10.2005). Available from: http://www.iofbonehealth.org.
  15. Bruyère O., Roux C., Detilleux J. et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 2007; 92: 8: 3076-3081.
  16. Rozhinskaya L.Ya., Arapova S.D., Dzeranova L.K. i dr. Rezul'taty rossiiskogo mnogotsentrovogo issledovaniya effektivnosti i perenosimosti Bivalosa (strontsiya ranelata) u zhenshchin s postmenopauzal'nym osteoporozom. Osteoporoz i osteopatii 2007; 3: 24-30.
  17. Dreval' A.V., Marchenkova L.A., Kryukova I.V. i dr. Effektivnost', perenosimost' i komplaentnost' alendronata natriya (70 mg 1 raz v nedelyu) pri lechenii postmenopauzal'nogo osteoporoza. Osteoporoz i osteopatii 2006; 2: 13-17.
  18. Rizzoli R., Greenspan S.L. at al. Two-years results of onse-weekly administration of Alendronate 70 mg for the treatment of postmenopausal osteoporosis J Bone Min Res 2002; 17: 1988-1996.
  19. Massari F., Zanchetta S.R. et al. PTH levels in posmenopausal women with osteoporosis treated with alendronate. J Bone Min Res 1997; 12 (Suppl 1): 4

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.